Clinical trial · Observational
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
NCT02747355CI-TRIAL-00036621unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In adrenal tumors, the investigators will examine if there is any correlation between WIESS criteria, prognosis of the tumor, and the different labeling index of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53, NEUROPILIN -1, METALLOTHIONEIN, SEMAPHORIN-3A.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenal Cortex Diseases | — | UNRESOLVED | — |
| Adrenal Cortex Neoplasms | Adrenal Cortical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- MCM3 expression
- timeFrame
- 1 year
- description
- Difference in MCM3 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
- measure
- MCM2 expression
- timeFrame
- 1 year
- description
- Difference in MCM2 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
- measure
- P53 expression
- timeFrame
- 1 year
- description
- Difference in P53 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
- measure
- NEUROPILIN -1 expression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adrenal carcinoma * adrenal adenoma * normal adrenal tissue Exclusion Criteria: * NA
References
Publications (0)
Data not yet available
No reference posted for this study.